The Hong Kong Special Administrative Region Government approves the emergency use right of Fuxitai Coronary vaccine in Hong Kong. It is expected that this vaccine will be transported to Hong Kong at the end of this month.
According to the Hong Kong Sing Tao Daily, the Hong Kong Government announced on Friday (November 18) that Hong Kong Medical and Health Director Lu Chongmao recognized Fosun Pharmaceutical or Germany in accordance with the regulations of prevention and control of diseases (vaccines).Biontech's Fuzitai primitive strain or Omikon mutant BA.4 and BA.5 dual -valent vaccine in Hong Kong is urgently used in Hong Kong.
The Hong Kong Consultant and Expert Committee believes that under the current crown disease epidemic, the use of Fubaitai binary vaccines as reinforcements to prevent crown disease is greater than risks.
After referenced the relevant opinions and measured the threat of crown disease to the public health, Lu Paimao believes that the use of two -price vaccine is necessary and meet the public interest. ThereforeUse in Hong Kong.However, in order to ensure the continuous safety, effectiveness and quality assurance of the vaccine, Lu Chongmao's additional conditions to the above recognition, including requiring the applicant to continue to submit the latest clinical data, safe update report, and the quality proof document of the quality of each vaccine for pharmaceutical plants.wait.
According to the information provided by the pharmaceutical factory, the first batch of vaccines are expected to arrive in Hong Kong from Germany at the end of November.
The report also said that these binary vaccines can be used as another choice for the fourth dose vaccine, and the two vaccines currently provided, namely Koxing and Fuxitai vaccine, can continue to make the fourth dose of the fourth dose.use.
